MCID: PRG002
MIFTS: 42

Progesterone-Receptor Positive Breast Cancer malady

Cancer diseases category

Summaries for Progesterone-Receptor Positive Breast Cancer

About this section
Sources:
32MalaCards
See all sources

Fully expand this MalaCard

Export this MalaCard
MalaCards: Progesterone-Receptor Positive Breast Cancer is related to breast cancer and estrogen-receptor positive breast cancer. An important gene associated with Progesterone-Receptor Positive Breast Cancer is ESR2 (estrogen receptor 2 (ER beta)), and among its related pathways are Plasma membrane estrogen receptor signaling and Apoptosis and survival Anti-apoptotic action of nuclear ESR1 and ESR2. The compounds 5fluorouracil and letrozole have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and skin, and related mouse phenotypes are endocrine/exocrine gland and integument.

Aliases & Classifications for Progesterone-Receptor Positive Breast Cancer

About this section
Sources:
8Disease Ontology
See all sources

Classifications:

Malacards categories (disease lists): (See all malacards categories)
Global: Cancer diseases


Aliases & Descriptions:

progesterone-receptor positive breast cancer 8


External Ids:

Disease Ontology8 DOID:0060077

Related Diseases for Progesterone-Receptor Positive Breast Cancer

About this section
Sources:
17GeneCards, 18GeneDecks
See all sources

Diseases in the Progesterone-Receptor Negative Breast Cancer family:

progesterone-receptor positive breast cancer

Diseases related to Progesterone-Receptor Positive Breast Cancer via text searches within MalaCards or GeneCards/GeneDecks gene sharing:

(show top 50)    (show all 89)
idRelated DiseaseScoreTop Affiliating Genes
1breast cancer31.2VEGFA, CYP19A1, PGR, ERBB2, ESR1, ESR2
2estrogen-receptor positive breast cancer10.7
3estrogen-receptor negative breast cancer10.5
4progesterone-receptor negative breast cancer10.5
5vascular cancer10.3
6adenoma10.0ESR2
7leiomyosarcoma10.0PGR
8fibromatosis10.0PGR
9sertoli-leydig cell tumor10.0PGR
10colon adenocarcinoma10.0ESR2
11osteoarthritis10.0ESR2
12hemangioma10.0VEGFA
13leukemia10.0ESR2
14arthritis10.0ESR2
15cerebral meningioma10.0PGR
16insulin resistance10.0ESR2
17blindness10.0VEGFA
18azoospermia10.0ESR2
19hepatocellular carcinoma10.0VEGFA
20leydig cell tumor10.0CYP19A1
21cryptorchidism10.0CYP19A1
22alzheimer's disease10.0ESR2
23uterine carcinosarcoma10.0ERBB2
24aromatase deficiency10.0CYP19A1
25graves' disease10.0ESR2
26astrocytoma10.0VEGFA
27germ cell cancer10.0ESR2
28atherosclerosis10.0ESR2
29melanoma10.0VEGFA
30pituitary adenoma10.0ESR2
31polycystic ovary syndrome10.0ESR2, CYP19A1
32estrogen excess10.0CYP19A1, PGR
33rheumatoid arthritis10.0VEGFA, ESR2
34ovarian cyst10.0CYP19A1, ESR2
35diabetes mellitus10.0VEGFA, ESR2
36stomach cancer10.0ERBB2, VEGFA
37sertoli cell tumor10.0CYP19A1, PGR
38lung cancer10.0VEGFA, ERBB2
39malignant mixed mullerian tumor10.0ERBB2, PGR
40male infertility10.0CYP19A1, ESR2
41pituitary tumors10.0ESR1, ESR2
42osteosarcoma10.0ESR2, ESR1
43progesterone resistance10.0PGR, ESR1
44choriocarcinoma10.0ESR2, CYP19A1
45bilateral breast cancer10.0ESR1, PGR
46prolactinoma10.0ESR2, ESR1
47smooth muscle tumor10.0ESR1, PGR
48retinopathy of prematurity10.0VEGFA
49lymphangioleiomyomatosis10.0ESR1, PGR
50cribriform carcinoma10.0PGR, ESR1

Graphical network of the top 20 diseases related to Progesterone-Receptor Positive Breast Cancer:



Diseases related to progesterone-receptor positive breast cancer

Clinical Features for Progesterone-Receptor Positive Breast Cancer

About this section

Drugs & Therapeutics for Progesterone-Receptor Positive Breast Cancer

About this section
Sources:
5CenterWatch, 41NIH Clinical Center, 6ClinicalTrials
See all sources

Approved drugs:

Search CenterWatch for Progesterone-Receptor Positive Breast Cancer

Drug clinical trials:

Search ClinicalTrials for Progesterone-Receptor Positive Breast Cancer

Search NIH Clinical Center for Progesterone-Receptor Positive Breast Cancer

Search CenterWatch for Progesterone-Receptor Positive Breast Cancer

Genetic Tests for Progesterone-Receptor Positive Breast Cancer

About this section

Anatomical Context for Progesterone-Receptor Positive Breast Cancer

About this section
Sources:
32MalaCards
See all sources

MalaCards organs/tissues related to Progesterone-Receptor Positive Breast Cancer:

32
Breast, Lymph node, Skin, Endothelial

Animal Models for Progesterone-Receptor Positive Breast Cancer or affiliated genes

About this section
Sources:
36MGI
See all sources

Publications for Progesterone-Receptor Positive Breast Cancer

About this section
Sources:
50PubMed
See all sources

Articles related to Progesterone-Receptor Positive Breast Cancer:

(show all 37)
idTitleAuthorsYear
1
Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer. (23788750)
2013
2
Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer. (23579222)
2013
3
Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype. (23971947)
2013
4
A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort study. (22548922)
2012
5
Progesterone and levonorgestrel regulate expression of 17I^HSD-enzymes in progesterone receptor positive breast cancer cell line T47D. (22564730)
2012
6
Use of tamoxifen with postsurgical irradiation may improve survival in estrogen and progesterone receptor-positive male breast cancer. (21421521)
2011
7
A progesterone-receptor-positive huge retroperitoneal tumour mimics metastasis in a breast cancer patient: sarcomatoid renal cell carcinoma. (21618856)
2011
8
Estrogen receptor positive operable breast cancer: does menopausal status impact on HER2 and progesterone receptor status? (21700456)
2011
9
Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy]. (21029696)
2010
10
Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer. (20705559)
2010
11
Immunohistochemical expression of glycodelin in breast cancer correlates with estrogen-receptor alpha and progesterone-receptor A positivity. (19224449)
2009
12
Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor. (19130322)
2009
13
Positive association between nuclear Runx2 and oestrogen-progesterone receptor gene expression characterises a biological subtype of breast cancer. (19632824)
2009
14
Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer? (19703124)
2009
15
Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy. (18302747)
2008
16
Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor-positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negative (triple-negative) breast cancer. (17581308)
2007
17
Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients. (17293115)
2007
18
Progesterone receptor in estrogen receptor-positive breast cancer: the association between HER-2 and lymph node involvement is age related. (16735717)
2006
19
Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial. (16467123)
2006
20
Estrogen receptor alpha-negative and progesterone receptor-positive breast cancer: lab error or real entity? (17189985)
2006
21
Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer. (16467118)
2006
22
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. (16145046)
2005
23
Progesterone-independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology. (15563544)
2005
24
Mouse mammary tumor-like virus is associated with p53 nuclear accumulation and progesterone receptor positivity but not estrogen positivity in human female breast cancer. (15240531)
2004
25
Cyclo-oxygenase-2 (COX-2) mRNA expression correlates with progesterone receptor positivity in human breast cancer. (12740157)
2003
26
Accumulation of uPA-PAI-1 complexes inside the tumour cells is associated with axillary nodal invasion in progesterone-receptor-positive early breast cancer. (12556966)
2003
27
Natural history of estrogen receptor-negative, progesterone receptor-positive breast cancer. (12408471)
2002
28
Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu. (11221879)
2001
29
In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. (9865902)
1998
30
Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group. (9196144)
1997
31
Estrogen receptor-negative/progesterone receptor-positive Evsa-T mammary tumor cells: a model for assessing the biological property of this peculiar phenotype of breast cancers. (9570382)
1997
32
Immunohistochemical detection of estradiol and progesterone receptors in paraffin sections after treatment with microwaves. Comparison with biochemical assay of receptors in a series of 123 breast cancers with determination of the threshold of optimal positivity]. (9221007)
1997
33
Sequence variants of the estrogen receptor (ER) gene found in breast cancer patients with ER negative and progesterone receptor positive tumors. (8973592)
1996
34
A study on methodology and the criteria for positive immunohistostaining of estrogen and progesterone receptors in paraffin embedded sections of breast cancer]. (9388856)
1996
35
Recurrence-free survival in breast cancer improved by adjuvant tamoxifen--especially for progesterone receptor positive tumors with a high proliferation. (7579503)
1995
36
Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. (1634918)
1992
37
Tumor-proliferative activity, progesterone receptor status, estrogen receptor level, and clinical outcome of estrogen receptor-positive advanced breast cancer. (2334898)
1990

Genetic Variations for Progesterone-Receptor Positive Breast Cancer

About this section

Expression for genes affiliated with Progesterone-Receptor Positive Breast Cancer

About this section
Sources:
1BioGPS, 15Gene Expression Omnibus DataSets
See all sources
Expression patterns in normal tissues for genes affiliated with Progesterone-Receptor Positive Breast Cancer

Search GEO for disease gene expression data for Progesterone-Receptor Positive Breast Cancer.

Pathways for genes affiliated with Progesterone-Receptor Positive Breast Cancer

About this section
Sources:
37NCBI BioSystems Database, 12EMD Millipore, 51QIAGEN, 53Reactome, 49PharmGKB, 29KEGG
See all sources

Pathways related to Progesterone-Receptor Positive Breast Cancer according to GeneCards/GeneDecks:

(show all 15)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
19.2ESR2, ESR1
2
Apoptosis and survival Anti-apoptotic action of nuclear ESR1 and ESR2
Hide members
9.2ESR2, ESR1
39.2ESR2, ESR1
4
Development Ligand-dependent activation of the ESR1/AP-1 pathway
Hide members
9.1ESR1, VEGFA
59.1CYP19A1, PGR, ESR2
6
Hide members
8.8PGR, ESR1, ESR2
7
Hide members
8.7ESR2, ESR1, CYP19A1
8
Development Endothelin-1/EDNRA signaling
Hide members
8.7VEGFA, ESR1, ESR2
9
Development Prolactin receptor signaling
Hide members
8.6ESR2, ESR1, ERBB2
10
Development Ligand-independent activation of ESR1 and ESR2
Hide members
8.6ESR2, ESR1, ERBB2
118.6VEGFA, CYP19A1, ESR1
12
Hide members
8.6ESR1, ERBB2, PGR
13
Hide members
8.5VEGFA, ERBB2, ESR1
148.5VEGFA, ERBB2, ESR1
158.1ESR2, ESR1, ERBB2, VEGFA

Compounds for genes affiliated with Progesterone-Receptor Positive Breast Cancer

About this section
Sources:
44Novoseek, 49PharmGKB, 59Tocris Bioscience, 11DrugBank, 24HMDB, 28IUPHAR, 2BitterDB
See all sources

Compounds related to Progesterone-Receptor Positive Breast Cancer according to GeneCards/GeneDecks:

(show top 50)    (show all 142)
idCompoundScoreTop Affiliating Genes
15fluorouracil449.7ERBB2, PGR
2letrozole44 49 59 1112.3ERBB2, PGR, CYP19A1
3trilostane44 1110.1ESR1, ESR2, PGR
4idoxifene449.0ESR1, PGR, CYP19A1
55alpha-androstane-3alpha,17beta-diol449.0ESR1, ESR2, CYP19A1
6naringenin44 119.9CYP19A1, ESR2, ESR1
7vinorelbine44 119.9VEGFA, CYP19A1, ERBB2
8fadrozole448.8CYP19A1, ESR1, ERBB2
9tibolone448.8ESR1, CYP19A1, PGR
10danazol44 11 2410.8ESR1, PGR, CYP19A1
11capecitabine44 49 1110.8VEGFA, CYP19A1, PGR, ERBB2
12estradiol benzoate448.7CYP19A1, ESR1, ESR2, PGR
13nandrolone44 249.7CYP19A1, PGR, ESR1, ESR2
14leuprolide acetate448.7PGR, ESR2, ESR1, CYP19A1
15bisphenol a448.7ESR1, CYP19A1, PGR, ESR2
16clomiphene citrate448.6ESR2, ESR1, PGR, CYP19A1
17levonorgestrel44 59 28 1111.6ESR1, CYP19A1, PGR, ESR2
18steroidal448.6CYP19A1, PGR, ESR1, ESR2
19diethylstilbestrol44 28 1110.6ESR2, ESR1, PGR, CYP19A1
2017beta-hydroxysteroid448.6ESR2, CYP19A1, ESR1, PGR
21progestins448.6ESR1, ESR2, PGR, CYP19A1
22estrone44 28 11 2411.5ESR2, ESR1, PGR, CYP19A1
23radicicol44 59 1110.5VEGFA, ERBB2, ESR1
24dihydrotestosterone44 28 11 2411.5ESR2, PGR, CYP19A1, ESR1
25megestrol acetate448.5ERBB2, PGR, CYP19A1, ESR1
26anastrozole44 119.5PGR, CYP19A1, ERBB2, ESR1
27lapatinib44 49 1110.4CYP19A1, ERBB2, ESR1, PGR
28geldanamycin44 49 59 1111.3ESR1, ERBB2, PGR, VEGFA
29cyclophosphamide44 49 1110.2ESR1, PGR, CYP19A1, ERBB2
30steroid448.2ESR1, ERBB2, CYP19A1
31mifepristone44 59 28 1111.1PGR, ESR2, CYP19A1, ESR1, VEGFA
32exemestane49 44 59 1111.1ERBB2, PGR, ESR1, ESR2, CYP19A1
33toremifene44 119.1ESR2, CYP19A1, ESR1, ERBB2, PGR
34fulvestrant44 49 28 1111.1ESR2, ESR1, ERBB2, CYP19A1, PGR
35raloxifene44 28 49 1111.1ESR1, CYP19A1, ESR2, ERBB2, PGR
364-hydroxytamoxifen448.1ESR2, CYP19A1, PGR, ERBB2, ESR1
37resveratrol44 59 11 2411.0ESR2, ERBB2, PGR, VEGFA, ESR1
38gefitinib44 49 1110.0ESR2, VEGFA, ESR1, ERBB2, CYP19A1
39gnrh448.0CYP19A1, ESR2, PGR, ERBB2, ESR1
40taxane448.0ERBB2, ESR1, PGR, CYP19A1, VEGFA
41trastuzumab44 49 1110.0ERBB2, PGR, CYP19A1, VEGFA, ESR1
42paraffin447.9ESR2, PGR, ERBB2, VEGFA, ESR1
43docetaxel44 49 59 1110.9PGR, VEGFA, ESR1, ERBB2, CYP19A1
44paclitaxel44 49 119.8CYP19A1, ERBB2, PGR, VEGFA, ESR1
45progesterone44 59 28 11 2411.6ESR1, ESR2, CYP19A1, PGR, ERBB2
46progestin447.6ERBB2, ESR2, ESR1, PGR, CYP19A1, VEGFA
47tamoxifen44 49 28 1110.5ESR2, ERBB2, ESR1, CYP19A1, PGR, VEGFA
48testosterone44 59 11 2410.5ESR2, ESR1, ERBB2, PGR, CYP19A1
49doxorubicin44 49 119.5ESR1, ERBB2, ESR2, PGR, CYP19A1, VEGFA
50genistein44 28 59 2 11 2412.5ESR1, CYP19A1, VEGFA, PGR, ESR2, ERBB2

GO Terms for genes affiliated with Progesterone-Receptor Positive Breast Cancer

About this section
Sources:
16Gene Ontology
See all sources

Biological processes related to Progesterone-Receptor Positive Breast Cancer according to GeneCards/GeneDecks:

(show all 11)
idNameGO IDScoreTop Affiliating Genes
1uterus developmentGO:0600659.5ESR2, ESR1
2vagina developmentGO:0600689.5ESR2, ESR1
3ovarian follicle developmentGO:0015419.4ESR2, VEGFA
4intracellular estrogen receptor signaling pathwayGO:0305209.4ESR1, ESR2
5positive regulation of cell adhesionGO:0457859.3VEGFA, ERBB2
6mammary gland alveolus developmentGO:0607499.3VEGFA, ESR1
7positive regulation of epithelial cell proliferationGO:0506799.3ERBB2, VEGFA
8androgen metabolic processGO:0082099.3CYP19A1, ESR1
9positive regulation of MAP kinase activityGO:0434069.0ERBB2, VEGFA
10transcription initiation from RNA polymerase II promoterGO:0063678.9PGR, ESR1, ESR2
11signal transductionGO:0071658.2ESR2, ESR1, ERBB2, PGR

Molecular functions related to Progesterone-Receptor Positive Breast Cancer according to GeneCards/GeneDecks:

(show all 7)
idNameGO IDScoreTop Affiliating Genes
1ligand-activated sequence-specific DNA binding RNA polymerase II transcription factor activityGO:0048799.6ESR2, PGR
2estrogen response element bindingGO:0340569.3ESR2, ESR1
3estrogen receptor activityGO:0302849.2ESR1, ESR2
4core promoter sequence-specific DNA bindingGO:0010469.1ESR2, ESR1
5steroid bindingGO:0054968.9ESR2, ESR1, PGR
6steroid hormone receptor activityGO:0037078.9ESR2, ESR1, PGR
7enzyme bindingGO:0198998.5ESR2, ESR1, PGR

Products for genes affiliated with Progesterone-Receptor Positive Breast Cancer

About this section
  • Antibodies
  • Proteins
  • Lysates
  • Antibodies

Sources for Progesterone-Receptor Positive Breast Cancer

About this section
3CDC
13ExPASy
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
34MeSH
35MESH via Orphanet
36MGI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
50PubMed
51QIAGEN
57SNOMED-CT via Orphanet
60UMLS
61UMLS via Orphanet